Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Elligo Health Research

Neither a doctor nor a teaching hospital

Research payments

$844,616

185 payments

Through program year 2025, Elligo Health Research is reported as receiving $844,616 in research payments, across 185 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $17,221 7
2024 Research $355,077 59
2023 Research $138,709 21
2022 Research $105,951 18
2021 Research $98,326 50
2020 Research $81,179 22
2019 Research $48,153 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. Biogen, Inc. $441,630 10 payments
  2. Ferring International Pharmascience Center US $115,909 43 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $78,889 41 payments
  4. Amgen Inc. $71,272 3 payments
  5. Pfizer Inc. $56,798 14 payments
  6. Allergan Inc. $50,036 12 payments
  7. Ironwood Pharmaceuticals, Inc $9,766 8 payments
  8. Insmed, Inc. $7,295 47 payments
  9. AbbVie, Inc. $6,484 1 payment
  10. Roche Molecular Systems, Inc. $5,869 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $191,211 3 payments
  2. A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) $187,623 2 payments
  3. A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial Assessing Efficacy, Safety, Dose-response of Quinagolide Vaginal Rings Administered Sequentially for 8 Menstrual Cycles in Women With Moderate-Severe Endometriosis-related Pain $77,740 22 payments
  4. OCEANa-Outcomes P3 CV $61,430 2 payments
  5. A Phase 1 Openlabel Study to Evaluate the Pharmacokinetics Safety and Tolerability of Orally Administered Nirmatrelvirritonavir in Pregnant Women With Mildtomoderate Covid19 $53,599 13 payments
  6. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $47,969 9 payments
  7. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $45,258 3 payments
  8. A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial Assessing Efficacy, Safety, Dose-response of Quinagolide Vaginal Rings Administered Sequentially for 4 Menstrual Cycles in Women With Moderate-Severe Endometriosis-related Pain $30,910 11 payments
  9. BAY1454032, Essure System for Permanent Birth Control $30,602 14 payments
  10. BAY1454032 Essure System for Permanent Birth Control $26,847 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record